Zacks Investment Research
18 Jun 2026, 14:55 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Wall Street analysts have a consensus mean price target of $19.50 for Immix Biopharma (IMMX), representing a potential 113.6% upside from its current price of $9.13. — A significant gap between current price and analyst targets typically attracts buyers and increases short-term bullish sentiment for the specific ticker.
+0.60There is a positive trend in earnings estimate revisions for IMMX, with analysts agreeing that the company will report better earnings than previously estimated. — Upward earnings revisions are a strong fundamental indicator of growth and typically lead to positive price action.
+0.40Which stocks this story touches
Analysts indicate significant upside potential with a mean price target of $19.5 and positive earnings estimate revisions.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
